ANTX- An2 Therapeutics, Inc.

Name: An2 Therapeutics, Inc. Insider Trading Data
Creator: U.S. Securities and Exchange Commission
License: https://www.sec.gov/privacy#accessibility

An2 Therapeutics, Inc. (ANTX) has 14 insiders with recent SEC Form 4 filings, including 13 buys and 8 sells. ANTX is classified in the Biotechnology industry within the Health Care sector.

Insider Ownership

Role	Insider	Shares	Value	30d
Other	Eizen Joshua M	92.0K	$494.0K	-
Dir	Marks Gilbert Lynn	79.1K	$424.7K	-
Other	Williams Sarah Joanne	66.6K	$357.6K	-265
Other	Prior Stephen David	59.1K	$317.3K	-
Other	Chanda Sanjay	58.0K	$311.2K	-

Activity

Buys and sells only

Transactions

10 filings · page 6

Date	Insider	Role	Type	Shares	Price	Value	Chg%	3M	12M
Oct 26, 2022	Easom Eric74	Chief Executive Officer	Sell	9,350	$15.76	$147,357.73	-23.8%	-33.5%	-1.3%
Oct 21, 2022	Easom Eric74	Chief Executive Officer	Sell	21,244	$16.47	$349,911.80	-29.9%	-42.7%	-8.7%
Aug 4, 2022	Ra Capital Management, L.P.53	10% Owner	Buy	1,909	$7.51	$14,330.32	-	+71.4%	-5.5%
Jul 27, 2022	Ra Capital Management, L.P.53	10% Owner	Buy	23,219	$7.78	$180,674.69	+0.3%	+90.0%	-1.1%
Jun 21, 2022	Ra Capital Management, L.P.53	10% Owner	Buy	302	$7.99	$2,412.98	-	+18.3%	-11.2%
Jun 14, 2022	Ra Capital Management, L.P.53	10% Owner	Buy	81,424	$7.95	$647,401.86	+1.1%	+1.8%	-8.6%
Mar 29, 2022	Ra Capital Management, L.P.53	10% Owner	Buy	1,666,666	$15.00	$24,999,990.00	+83.3%	-44.1%	-34.6%
Mar 29, 2022	Readnour Robin Shane52	Director	Buy	153,334	$15.00	$2,300,010.00	+20.4%	-44.1%	-34.6%
Mar 29, 2022	Adjuvant Global Health Technology Fund, L.P.73	10% Owner	Buy	166,666	$15.00	$2,499,990.00	+8.2%	-44.1%	-34.6%
Mar 29, 2022	Aziz Kabeer73	Director, 10% Owner	Buy	166,666	$15.00	$2,499,990.00	+8.2%	-44.1%	-34.6%

← PrevPage 6

Insider	Role	Shares	Value	Buys	Sells

Date	Ticker	Insider	Role	Type	Shares	Price	Value	Chg%	SEC